Here are 7 ASX 200 Stocks Winning During The Iran War…And Aren’t In The Soaring Oil and Gas Space!

Investors asked to name ASX 200 stocks winning during the Iran war would likely think of oil and gas stocks,…

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Despite the dour state of the markets right now, it could be time for certain ASX stocks that should be…

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

There are hard questions investors need to ask about their portfolio every now and again, because anyone telling you there’s…

The Mayo Clinic will use 4DX’s CT:VQ and investors are thrilled

Another day, another piece of good news from 4DX Medical (ASX:4DX), today news the Mayo Clinic would be employing the…

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences‘ colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view,…

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Prescient Therapeutics‘ (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of…

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff…

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear,…

ASX All Ordinaries Stocks: Here’s Why These 8 Companies Joined the Club In the Latest Rebalance!

Twice a year, specifically on the third Fridays of March and September, the list of ASX All Ordinaries Stocks changes…

Here are 4 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

We thought this was a perfect time to ponder the question,’ Why share prices fall after a capital raising’, in…

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The…

Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose

The Aussie dollar has been surging in recent weeks and there are ASX stocks that will benefit from a higher…

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon…

This company just made an IND submission to the US FDA, here’s why its a big step!

Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it…

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their…

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing…

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that…

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US…

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

NeuroScientific jumps on early Crohn’s stem cell results NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results…

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Island Pharmaceuticals Secures US Patent for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 12 per cent this week after announcing it…

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we’ve looked at Ozempic and other GLP-1 Drugs. Investors paid…

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look…

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert…

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB)…

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an…

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called…

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Neurizon Therapeutics (ASX: NUZ) just hit a major milestone. The FDA has cleared its lead drug NUZ-001 to enter the…

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at…

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Imugene wins FDA support, funding risk remains Imugene (ASX: IMU) received a major regulatory boost this week after the US…

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

On Monday December 22, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others…

This Phase 2 ASX Biotech stock is only at cash backing, but has enormous upside!

Phase 2 Biotech stocks on ASX tend to be capitalised at $40-110m, but Percheron Therapeutics (ASX:PER) is only at cash…

Is Argenica (ASX:AGN) a Contrarian Buy After 64% Collapse and New Validation Data?

Argenica Therapeutics (ASX: AGN) crashed 70% in September after Phase II trial results disappointed, wiping out over $100 million overnight.…

Aroa Biosurgery Delivers $8.9M Cash Swing and First Profit: Buy the Biotech Turnaround?

Aroa Biosurgery (ASX: ARX) just crossed a critical milestone, reporting its first profitable half-year result. The business swung to a…

Johnson and Johnson (NYSE:JNJ): Firmly on the Big Pharma M&A bandwagon

Johnson and Johnson (NYSE:JNJ) is arguably one of the big pharma companies least at risk from the Patent cliff. It…

Avita Medical (ASX:AVH): It hasn’t catapulted it to the heights envisioned (yet), but there’s hope for the 2026 and 2027

Avita Medical (ASX:AVH/NDQ:RCEL) is a particularly peculiar healthcare stock. The company, these days based in the Californian city of Valencia…

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

$100bn biotechs like Vertex Pharmaceuticals (NDQ:VRTX) typically get to their position through ‘blockbuster drugs’ with periods of market exclusivity, which…

Rejecting a takeover offer: Here are 6 ASX stocks that did and how it ended for them

Rejecting a takeover offer is a bold step for an ASX company to take. It is turning down sweet quick…

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

The dream run Pfizer had during the pandemic was not going to last forever. But while certain companies that derived…

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Biotech company Mesoblast (ASX:MSB) is the ultimate definition of a rollercoaster company. As of October 7, 2025, it is capped…

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Hear the term ‘Activist investors’ and you might think of GetUp, the progressive activist group that forced Woolworths to hold…

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Mere days after Artrya (ASX:AYA) obtained FDA approval for its heart-health technology, EBR Systems (ASX:EBR) has achieved that same feat.…

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics‘ suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been…

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a…

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

There’s another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed…

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

It’s taken a while to get here, but the US medical device company Imagion Biosystems (ASX: IBX), which listed on…

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria’s Post-Traumatic Stress…

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

4 years after listing and over 7 years after its founding, Artrya (ASX:AYA) achieved the aspiration of most ASX medtechs,…

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

Think of ‘America First’ ASX stocks and Island Pharmaceuticals (ASX:ILA) typically hasn’t come to mind, but its acquisition of Galidesivir…

4DMedical 100% Surge: Beginning of a Breakout or the Peak?

4DMedical Doubles in a Month: Momentum or Peak? A 100 percent share price surge in just one month will always…

Telix SEC Subpoena Explained: Why the Stock Plunged 31%

What Investors Need to Know About the Telix SEC Subpoena What happens when a fast-growing biotech lands a major U.S.…

Capital Gains Tax on Shares: Here’s How It Works And Whether Or Not the 50% Discount Could Be Wound Back

Capital Gains Tax on Shares is one of the most notable taxes investors will face. Here is Stocks Down Under’s…

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors,…

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Donald Trump’s Tariffs Could Hit CSL and other Aussie Biotechs…it is a reality that is sinking in for many investors.…

Atomo Diagnostics investors are excited about their fair share from Lumos Diagnostics’ A$487m distribution deal

Wednesday 16 July 2025 was a great day for Atomo Diagnostics (ASX:AT1) investors as shares climbed up to 56% higher…

Here are 5 ESG metrics to look at to give you an edge in investing!

Here are 5 ESG metrics to look at! 1. Employee Turnover Common criticisms of ESG metrics is that some have…

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the…

SDI (ASX:SDI): Will slow and steady win the race?

If you’re looking for a stock that’ll make you a fortune, SDI (ASX:SDI) might not be the best one for…

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this…

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

It is a New Financial Year, so it’s time to outline 11 Top ASX Stocks to Buy in FY26. Why…

Tetratherix Hits the ASX: What Investors Need to Know About This Fresh Life Sciences Listing

Tetratherix Limited (ASX: TTX) officially began trading on the Australian Securities Exchange following a successful initial public offering that raised…

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

It’s been a tough few years for ASX biotech small caps. Even in the last 18 months, the market recovered…

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Israel’s strikes on Iran, and the subsequent responses, led to the typical “risk off” moves professional investors usually make when…

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

In the decade since fertility provider Monash IVF (ASX:MVF) listed, it was not an easy journey. Only a few months…

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left…

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

2025 has been, and will continue to be, a big year for Proteomics, which has just launched PromarkerD onto the…

This Time is Different: John Templeton said this phrase was costly in 1933, but here is when it may be true

‘The investor who says, “This time is different,” when in fact it’s virtually a repeat of an earlier situation, has…

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is…

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

After many decades at the helm of Berkshire Hathaway, Warren Buffett is retiring. After founding his empire in 1965, he…

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Dimerix has been targeting a US licensing deal for DMX-200 and the dreams are now a reality as of this…

Stock Market Basics

Start Investing in Australia

Where to Invest In

Biotech Stocks

Get in touch

Follow us on